Lung

General

Molecular aspects



Topic Completed: 11 December 2020

Minor changes: 30 June 2021

Copyright: 2019-2021, PathologyOutlines.com, Inc.

See also: Lung-adenocarcinoma, Lung-squamous cell carcinoma

Nat Pernick, M.D.
Page views in 2021 to date: 342
Cite this page: Pernick N. Molecular aspects. PathologyOutlines.com website. https://www.pathologyoutlines.com/topics/lungtumormolecularaspects.html. Accessed October 25th, 2021.
Definition / general
  • Based on NCCN guidelines, version 7.2019, initial step for advanced or metastatic disease is establishing histologic subtype and obtaining tissue for molecular testing (NCCN Guidelines for NSCLC (login required), PDF page 37)
Adenocarcinoma, Large cell, NSCLC-NOS
  • Recommended molecular testing:
  • Broad molecular profiling is recommended to identify rare drive mutations, either because they may have effective drugs or support eligibility in specific clinical trials
Squamous cell carcinoma
  • Consider EGFR mutation and ALK testing for never smokers, small biopsies or mixed histology
  • Consider ROS1 and BRAF testing in small biopsies or mixed histology
  • PDL1
  • Broad molecular profiling is recommended to identify rare drive mutations, either because they may have effective drugs or support eligibility in specific clinical trials
Back to top
Image 01 Image 02